Figure 3
Levels of (a) IL-6 and (b) IL-8 in A549 cells treated with FCBD or FCBD:std with or without CB1 or CB2 inverse agonists (IA), TRPA1 blocker, or TRPV1 or TRPV2 antagonists. Cells were treated with 300 ng/mL TNFα and FCBD (FCBD) and FCBD:std (FCBD:std) at a concentration of 3.4 and 4.1 μg/mL, respectively, in the presence or absence of IA of CB1 (5 µM) or CB2 (5 and 7.5 µM for IL-6 and IL-8, respectively), a TRPA1 blocker (10 µM), or TRPV1 or TRPV2 antagonists (10 µM) for 4 h. Dexamethasone (Dex) served as a positive control at 4 µg/mL. Control (0.4% v/v methanol + 2% v/v dimethyl sulfoxide [DMSO]) treatment served as the solvent (vehicle) control; TNFα is TNFα+ solvent control treatment. Error bars indicate ± sem (n = 3). Bars labeled with different letters are significantly different from all combinations of pairs according to the Tukey–Kramer HSD test (P ≤ 0.05).
